At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 45 enrolled

Drug / intervention

Capecitabine +1 moredrug

Likely dose

Capecitabine 1600mg/m2from record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00290693

NCT00290693Phase 2Completed

Compare CT.gov

A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients "CapTere"

University of Miami·interventional·Posted Feb 13, 2006·Updated Dec 2, 2017

In Brief

A Phase 2 clinical trial evaluating Capecitabine and Docetaxel for Pancreatic Cancer. Completed, enrolled 45 participants across 3 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving capecitabine together with docetaxel works in treating patients with recurrent or progressive metastatic pancreatic cancer.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsPancreatic Cancer

CountriesUnited States

Collaborators--

Timeline

Phase 2CompletedFinished

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJul 2004

First PostedFeb 2006

Primary CompletionAug 2008

Study CompletionJun 2010

TodayJul 2026

First PostedFeb 13, 2006

Enrollment StartJul 1, 2004

Primary CompletionAug 1, 2008

Study CompletionJun 1, 2010

TodayJul 2, 2026

Enrollment to primary: 4.1 yearsPosted 20.4 years ago

Interventions

Capecitabinedrug

Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle

Docetaxeldrug

30 mg/m2, IV, days 1 and 8 every 3 weeks